Evaluation of Steroid Pulse Therapy Responsiveness in Myelin-Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis.

Autor: Takai Y; Department of Ophthalmology, Inouye Eye Hospital, Tokyo, JPN., Yamagami A; Department of Ophthalmology, Inouye Eye Hospital, Tokyo, JPN., Iwasa M; Department of Ophthalmology, Inouye Eye Hospital, Tokyo, JPN., Inoue K; Department of Ophthalmology, Inouye Eye Hospital, Tokyo, JPN., Wakakura M; Department of Ophthalmology, Inouye Eye Hospital, Tokyo, JPN., Takahashi T; Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, JPN., Tanaka K; Department of Animal Model Development, Brain Research Institute, Niigata University, Niigata, JPN.
Jazyk: angličtina
Zdroj: Cureus [Cureus] 2024 Mar 21; Vol. 16 (3), pp. e56673. Date of Electronic Publication: 2024 Mar 21 (Print Publication: 2024).
DOI: 10.7759/cureus.56673
Abstrakt: Purpose: Myelin-oligodendrocyte glycoprotein antibody-positive optic neuritis (MOGON) is usually responsive to the steroid, but, for some patients, steroid pulse therapy alone may be inadequate. This study aimed to investigate the factors predicting the response to steroid pulse therapy in MOGON.
Methods: This study included 17 patients (24 eyes) with MOGON, who received single steroid pulse therapy as initial treatment. Best corrected visual acuity (BCVA) and mean deviation (MD) values after treatment were examined concerning findings at onset.
Results: No correlation was found between BCVA at onset and after treatment, but a correlation was observed between MD values at onset and after treatment (correlation coefficient 0.48, p=0.01, Spearman's rank correlation coefficient). Age, gender, duration from onset to treatment, magnetic resonance imaging findings, and optical coherence tomography findings did not affect visual function after treatment.
Conclusions: Severe visual field impairment at onset may indicate that additional treatment may be necessary.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright © 2024, Takai et al.)
Databáze: MEDLINE